Document Detail


Fish oil reduces heart rate and oxygen consumption during exercise.
MedLine Citation:
PMID:  19034030     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dietary omega-3 polyunsaturated fatty acids (PUFAs) are readily incorporated into heart and skeletal muscle membranes where, in the heart, animal studies show they reduce O2 consumption. To test the hypothesis that omega-3 PUFAs alter O2 efficiency in humans, the effects of fish oil (FO) supplementation on O2 consumption during exercise were evaluated. Sixteen well-trained men (cyclists), randomly assigned to receive 8 x 1 g capsules per day of olive oil (control) or FO for 8 weeks in a double-blind, parallel design, completed the study (control: n = 7, age 27.1 +/- 2.7 years; FO: n = 9, age 23.2 +/- 1.2 years). Subjects used an electronically braked cycle ergometer to complete peak O2 consumption tests (VO 2peak) and sustained submaximal exercise tests at 55% of peak workload (from the VO 2peak test) before and after supplementation. Whole-body O2 consumption and indirect measurements of myocardial O2 consumption [heart rate and rate pressure product (RPP)] were assessed. FO supplementation increased omega-3 PUFA content of erythrocyte cell membranes. There were no differences in VO 2peak (mL kg(-1) min(-1)) (control: pre 66.8 +/- 2.4, post 67.2 +/- 2.3; FO: pre 68.3 +/- 1.4, post 67.2 +/- 1.2) or peak workload after supplementation. The FO supplementation lowered heart rate (including peak heart rate) during incremental workloads to exhaustion (P < 0.05). In addition, the FO supplementation lowered steady-state submaximal exercise heart rate, whole-body O2 consumption, and RPP (P < 0.01). Time to voluntary fatigue was not altered by FO supplementation. This study indicates that FOs may act within the healthy heart and skeletal muscle to reduce both whole-body and myocardial O2 demand during exercise, without a decrement in performance.
Authors:
Gregory E Peoples; Peter L McLennan; Peter R C Howe; Herbert Groeller
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  52     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-22     Completed Date:  2009-02-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  540-7     Citation Subset:  IM    
Affiliation:
Smart Foods Centre, School of Health Sciences, University of Wollongong, Wollongong, NSW, Australia. peoples@uow.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Capsules
Dietary Supplements*
Docosahexaenoic Acids / administration & dosage
Double-Blind Method
Eicosapentaenoic Acid / administration & dosage
Erythrocyte Membrane / drug effects,  metabolism
Exercise / physiology*
Fish Oils / administration & dosage*,  blood
Heart Rate / drug effects*
Humans
Male
Membrane Lipids / blood
Muscle Fatigue / drug effects
Muscle, Skeletal / drug effects*,  metabolism
Myocardium / metabolism*
Oxygen Consumption / drug effects*
Time Factors
Young Adult
Chemical
Reg. No./Substance:
0/Capsules; 0/Fish Oils; 0/Membrane Lipids; 1553-41-9/Eicosapentaenoic Acid; 25167-62-8/Docosahexaenoic Acids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemi...
Next Document:  Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheteri...